Does The U.S. Biosimilar Space Have A Case Of "Progressophobia"?

By Anna Rose Welch, Editorial & Community Director, Advancing RNA

As I was running out the door of the 2017 CBI Biosimilars Summit last year, I stopped and introduced myself to Eric Sjogren, director of strategic business intelligence for Merck. Sjogren had just finished the final presentation of the conference, which turned into a conversation with attendees about predictions for the biosimilar industry in 2017. Little did we both know, eight months later, we’d be signing a contract to become co-presenters at the 2018 CBI Biosimilars Summit this past January.

We opened the conference by revealing whether our 2017 biosimilar predictions had come true and how we expected them to take shape in 2018. (Naturally, this assignment also led to the creation of 30-plus biosimilar memes and a rewritten, biosimilar-themed Star Wars introduction — Biosimilar Wars, if you will. These were more popular than the presentation.)